MX2018003197A - Métodos relacionados a composiciones de células dentríticas activadas y tratamientos inmunoterapéuticos para sujetos con cánceres avanzados. - Google Patents
Métodos relacionados a composiciones de células dentríticas activadas y tratamientos inmunoterapéuticos para sujetos con cánceres avanzados.Info
- Publication number
- MX2018003197A MX2018003197A MX2018003197A MX2018003197A MX2018003197A MX 2018003197 A MX2018003197 A MX 2018003197A MX 2018003197 A MX2018003197 A MX 2018003197A MX 2018003197 A MX2018003197 A MX 2018003197A MX 2018003197 A MX2018003197 A MX 2018003197A
- Authority
- MX
- Mexico
- Prior art keywords
- activated dendritic
- cytokines
- dendritic cell
- subjects
- methods relating
- Prior art date
Links
- 210000004443 dendritic cell Anatomy 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000001024 immunotherapeutic effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 108090000695 Cytokines Proteins 0.000 abstract 3
- 102000004127 Cytokines Human genes 0.000 abstract 3
- 108010012236 Chemokines Proteins 0.000 abstract 2
- 102000019034 Chemokines Human genes 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 108010065805 Interleukin-12 Proteins 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 108090001007 Interleukin-8 Proteins 0.000 abstract 1
- 108700012920 TNF Proteins 0.000 abstract 1
- 230000020411 cell activation Effects 0.000 abstract 1
- 230000011748 cell maturation Effects 0.000 abstract 1
- 230000002596 correlated effect Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5421—IL-8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/72—Undefined extracts from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2313—Interleukin-13 (IL-13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
- G01N2333/5255—Lymphotoxin [LT]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5421—IL-8
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5434—IL-12
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
La presente descripción proporciona células dendríticas activadas y parcialmente maduras que producen niveles de citoquinas/quimiocinas, por ejemplo, uno o cualquier combinación de, y/o todos de IL-6, IL-8, IL-12 y/o TNFa, que se correlacionan con el resultado clínico mejorado, veces de sobrevivencia significativamente incrementadas y veces significativamente incrementadas para recurrencia de tumor o cáncer. Las cantidades de umbral determinadas de estas citoquinas pueden utilizarse para (i) una prueba de potencia inmunoterapéutica para células dendríticas activadas, (ii) seleccionar pacientes que responden, (iii) rechazar pacientes sin respuesta y (iv) detectar la activación de célula dendrítica o agentes de maduración que también pueden inducir la producción de la cantidad de umbral de las citoquinas/quimiocinas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562219058P | 2015-09-15 | 2015-09-15 | |
PCT/US2016/051781 WO2017048875A1 (en) | 2015-09-15 | 2016-09-14 | Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018003197A true MX2018003197A (es) | 2018-09-26 |
Family
ID=58289879
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018003197A MX2018003197A (es) | 2015-09-15 | 2016-09-14 | Métodos relacionados a composiciones de células dentríticas activadas y tratamientos inmunoterapéuticos para sujetos con cánceres avanzados. |
MX2022008806A MX2022008806A (es) | 2015-09-15 | 2018-03-14 | Metodos relacionados a composiciones de celulas dendriticas activadas y tratamientos inmunoterapeuticos para sujetos con canceres avanzados. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022008806A MX2022008806A (es) | 2015-09-15 | 2018-03-14 | Metodos relacionados a composiciones de celulas dendriticas activadas y tratamientos inmunoterapeuticos para sujetos con canceres avanzados. |
Country Status (17)
Country | Link |
---|---|
US (1) | US20190046568A1 (es) |
EP (2) | EP3350318B1 (es) |
JP (3) | JP6980650B2 (es) |
KR (1) | KR20180044430A (es) |
CN (2) | CN108291204A (es) |
AU (2) | AU2016323066B2 (es) |
BR (1) | BR112018005180B1 (es) |
CA (1) | CA2998614A1 (es) |
DK (1) | DK3350318T3 (es) |
ES (1) | ES2923769T3 (es) |
HK (1) | HK1258885A1 (es) |
HU (1) | HUE059560T2 (es) |
IL (2) | IL258071B (es) |
MX (2) | MX2018003197A (es) |
PL (1) | PL3350318T3 (es) |
RU (1) | RU2749610C2 (es) |
WO (1) | WO2017048875A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190076473A1 (en) * | 2017-09-14 | 2019-03-14 | Cellular Approaches, Inc. | Autologous and allogenic macrophages and monocytes for use in therapeutic methods |
CN110106145B (zh) * | 2019-06-12 | 2021-02-12 | 蓝莲(杭州)生物科技有限公司 | 一种未成熟树突状细胞培养液及其未成熟树突状细胞的制备方法 |
CA3157004A1 (en) * | 2019-10-07 | 2021-04-15 | Northwest Biotherapeutics, Inc. | In vitro methods and compositions for enhancing the activation of dendritic cells and t cells, and for inducing a th-1 immune response |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE260971T1 (de) | 1992-04-01 | 2004-03-15 | Univ Rockefeller | Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung |
US7659119B2 (en) | 1996-02-12 | 2010-02-09 | Argos Therapeutics, Inc. | Method and compositions for obtaining mature dendritic cells |
US6558951B1 (en) * | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
US20020094545A1 (en) | 2000-11-30 | 2002-07-18 | Harris Paul E. | Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads |
WO2003010292A2 (en) | 2001-07-25 | 2003-02-06 | Northwest Biotherapeutics, Inc. | Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors |
BRPI0312436A2 (pt) | 2002-06-19 | 2016-06-28 | Northwest Biotherapeutics Inc | dispositivo de filtragem de fluxo tangencial e métodos para enriquecimento em leucócito |
WO2004039968A1 (ja) * | 2002-10-30 | 2004-05-13 | Japan Science And Technology Agency | 骨髄由来の不死化樹状細胞株 |
US20060057120A1 (en) * | 2002-12-06 | 2006-03-16 | Northwest Biotherapeutics Inc. | Administration of dendritic cells partially matured in vitro for the treatment of tumors |
JP4762887B2 (ja) * | 2003-02-27 | 2011-08-31 | ノースウエスト バイオセラピューティクス,インコーポレイティド | 付加的なサイトカインの非存在下でgm−csfを用いる単球樹状前駆細胞からの樹状細胞の産生 |
US20060257359A1 (en) * | 2005-02-28 | 2006-11-16 | Cedric Francois | Modifying macrophage phenotype for treatment of disease |
TW200800252A (en) * | 2005-12-08 | 2008-01-01 | Northwest Biotherapeutics Inc | Compositions and methods for inducing the activation of immature monocytic dendritic cells |
JP5382529B2 (ja) * | 2007-09-10 | 2014-01-08 | 独立行政法人理化学研究所 | ヒト樹状細胞の評価方法およびヒト細胞免疫療法剤 |
EP2072617A1 (en) * | 2007-12-12 | 2009-06-24 | Trimed Biotech GmbH | Method for producing dendritic cells |
ES2679043T3 (es) * | 2009-05-15 | 2018-08-21 | Irx Therapeutics, Inc. | Inmunoterapia de vacuna |
CN103638517A (zh) * | 2013-12-04 | 2014-03-19 | 深圳市合一康生物科技有限公司 | 人树突状细胞疫苗制备的专用试剂盒 |
WO2016048872A1 (en) * | 2014-09-23 | 2016-03-31 | Neostem Oncology, Llc | Compositions, methods and kits used to determine potency of dendritic cells in cancer immunitherpay |
-
2016
- 2016-09-14 WO PCT/US2016/051781 patent/WO2017048875A1/en active Application Filing
- 2016-09-14 CN CN201680066721.XA patent/CN108291204A/zh active Pending
- 2016-09-14 EP EP16847253.8A patent/EP3350318B1/en active Active
- 2016-09-14 EP EP21189488.6A patent/EP3971285A3/en active Pending
- 2016-09-14 MX MX2018003197A patent/MX2018003197A/es unknown
- 2016-09-14 KR KR1020187010610A patent/KR20180044430A/ko active Search and Examination
- 2016-09-14 ES ES16847253T patent/ES2923769T3/es active Active
- 2016-09-14 AU AU2016323066A patent/AU2016323066B2/en active Active
- 2016-09-14 US US15/759,699 patent/US20190046568A1/en active Pending
- 2016-09-14 CA CA2998614A patent/CA2998614A1/en active Pending
- 2016-09-14 RU RU2018113435A patent/RU2749610C2/ru active
- 2016-09-14 BR BR112018005180-2A patent/BR112018005180B1/pt active IP Right Grant
- 2016-09-14 PL PL16847253.8T patent/PL3350318T3/pl unknown
- 2016-09-14 DK DK16847253.8T patent/DK3350318T3/da active
- 2016-09-14 CN CN202211533672.XA patent/CN116413420A/zh active Pending
- 2016-09-14 HU HUE16847253A patent/HUE059560T2/hu unknown
- 2016-09-14 JP JP2018513634A patent/JP6980650B2/ja active Active
-
2018
- 2018-03-13 IL IL258071A patent/IL258071B/en unknown
- 2018-03-14 MX MX2022008806A patent/MX2022008806A/es unknown
-
2019
- 2019-01-25 HK HK19101358.3A patent/HK1258885A1/zh unknown
-
2021
- 2021-09-09 IL IL286225A patent/IL286225A/en unknown
- 2021-11-17 JP JP2021186960A patent/JP2022028818A/ja not_active Withdrawn
-
2023
- 2023-07-27 AU AU2023208190A patent/AU2023208190A1/en active Pending
- 2023-11-28 JP JP2023200819A patent/JP2024019229A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2022008806A (es) | 2022-08-11 |
ES2923769T3 (es) | 2022-09-30 |
JP2018537949A (ja) | 2018-12-27 |
HK1258885A1 (zh) | 2019-11-22 |
US20190046568A1 (en) | 2019-02-14 |
EP3350318B1 (en) | 2022-04-13 |
DK3350318T3 (da) | 2022-07-11 |
CA2998614A1 (en) | 2017-03-23 |
AU2016323066A1 (en) | 2018-05-10 |
JP2024019229A (ja) | 2024-02-08 |
RU2749610C2 (ru) | 2021-06-16 |
EP3350318A4 (en) | 2019-11-13 |
HUE059560T2 (hu) | 2022-11-28 |
IL258071A (en) | 2018-05-31 |
RU2018113435A3 (es) | 2020-03-25 |
KR20180044430A (ko) | 2018-05-02 |
AU2023208190A1 (en) | 2023-08-17 |
IL286225A (en) | 2021-10-31 |
PL3350318T3 (pl) | 2022-08-16 |
WO2017048875A1 (en) | 2017-03-23 |
EP3971285A3 (en) | 2022-06-22 |
AU2016323066B2 (en) | 2023-04-27 |
JP2022028818A (ja) | 2022-02-16 |
CN116413420A (zh) | 2023-07-11 |
EP3350318A1 (en) | 2018-07-25 |
CN108291204A (zh) | 2018-07-17 |
BR112018005180B1 (pt) | 2023-11-28 |
RU2018113435A (ru) | 2019-10-16 |
IL258071B (en) | 2021-09-30 |
EP3971285A2 (en) | 2022-03-23 |
BR112018005180A2 (es) | 2018-10-02 |
JP6980650B2 (ja) | 2021-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019010382A (es) | Metodo de tratamiento de tumor inmunoterapeutico utilizando un agonista alfa,beta-selectivo del receptor de interleuquina-2 en combinacion con terapia de transferencia celular adoptiva. | |
PH12016500331A1 (en) | Survival benefit in patients with solid tumors with elevated c-reactive protein levels | |
GT201700200A (es) | Composiciones y métodos para activar la señalización dependiente del "estimulador del gen de interferon" | |
MX2022012013A (es) | Composiciones y metodos para transduccion de tumores. | |
BR112017014269A2 (pt) | células exterminadoras naturais e usos das mesmas | |
MX2017008421A (es) | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. | |
MX2018004600A (es) | Celulas aniquiladoras naturales y células ilc3 y usos de las mismas. | |
MY181994A (en) | Immuno-modulatory progenitor (imp) cell | |
MX2017006685A (es) | Tratamiento de enfermedades asociadas con activacion de celulas estrelladas hepaticas usando terapias reductoras de amoniaco. | |
MX2022008806A (es) | Metodos relacionados a composiciones de celulas dendriticas activadas y tratamientos inmunoterapeuticos para sujetos con canceres avanzados. | |
MX2018000267A (es) | Combinacion de inhibidores de histona desacetilasa y anticuerpo de ligando 1 de anti-muerte celular programada para el tratamiento de cancer. | |
MX2016012285A (es) | Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf. | |
CL2019002904A1 (es) | Biomarcadores para agentes terapéuticos contra el cáncer. | |
MX2021015411A (es) | Composiciones acopladoras especificas de macrofagos y metodos de uso de las mismas. | |
ZA201800931B (en) | Selection of patients for combination therapy | |
MX2021005395A (es) | Terapia del cáncer con células inmunitarias anti-liv1. | |
MX2020005640A (es) | Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama. | |
AU2024202398A1 (en) | Inhibition of SMARCA2 for treatment of cancer | |
MX2016015163A (es) | Biomarcadores mit y metodos para su uso. | |
MX2018016051A (es) | Composiciones y métodos para diagnosticar tipos de cáncer de pulmón usando perfiles de expresión génica. | |
PL3460052T3 (pl) | Ulepszone allogeniczne komórki dendrytyczne do stosowania w leczeniu nowotworu | |
PH12021550035A1 (en) | Combination therapy | |
MX2019007894A (es) | Composiciones y metodos para detectar el adn tumoral circulante. | |
WO2015187727A3 (en) | Molecular mammography | |
TR201811308T4 (tr) | Kanser kok hücrelerini azaltan anti-emp2 tedavisi. |